eculizumab (Soliris) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH repoDB

Active Ingredient History

NOW
  • Now
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$4373.1804

United States

$4981.6100 - $6031.3200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5g1.1 | 5g1.1-sc | eculizumab | h5g1.1 | h5g1.1-sc | h5g1.1 scfv | h5g1.1-scfv | h5g1.1 scfv (cdr) | h5g1.1vhc+h5g1.1vlc | pexelizumab | soliris

Organizations (56)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (3)


 

Atypical Hemolytic Uremic Syndrome

Hemoglobinuria

Hemoglobinuria, Paroxysmal

Experimental Indications - Clinical Trial Phases 1-4 (49)


 

Anemia, Hemolytic, Autoimmune (Phase 2)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 2)

Antiphospholipid Syndrome (Phase 2)

Asthma (Phase 2)

Atypical Hemolytic Uremic Syndrome ()

Blood Platelet Disorders (Phase 2)

Cardiopulmonary Bypass (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2)

Complement Pathway, Classical (Phase 2)

Coronary Artery Bypass (Phase 3)

Coronary Artery Disease (Phase 3)

COVID-19 (Phase 2)

Delayed Graft Function (Phase 2/Phase 3)

Dermatomyositis (Phase 2)

Diabetes Mellitus (Phase 2)

Drugs, Investigational (Phase 2)

End Stage Liver Disease (Early Phase 1)

Escherichia coli Infections (Phase 2/Phase 3)

Genetic Diseases, Inborn (Phase 2)

Glomerulonephritis, Membranoproliferative (Phase 2)

Graft Rejection (Phase 4)

Guillain-Barre Syndrome (Phase 3)

Healthy Volunteers (Phase 1)

HELLP Syndrome (Phase 2)

Hemoglobinuria ()

Hemoglobinuria, Paroxysmal ()

Hemolysis (Phase 1/Phase 2)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 2)

Kidney Transplantation (Phase 3)

Leukemia (Phase 3)

Livedoid Vasculopathy (Phase 4)

Macular Degeneration (Phase 2)

Maternal Health (Phase 1)

Multiple Organ Failure (Phase 2)

Myasthenia Gravis (Phase 3)

Myocardial Infarction (Phase 3)

Neonatology (Phase 1)

Neuromyelitis Optica (Phase 3)

Pediatrics (Phase 3)

Pre-Eclampsia (Phase 2)

Pregnancy Complications (Phase 2)

Renal Insufficiency (Phase 2)

Reperfusion Injury (Phase 2)

SARS-CoV-2 (Phase 2)

Thrombocytopenia (Phase 2)

Thrombotic Microangiopathies (Phase 3)

Vascular Grafting (Phase 4)

Ventricular Dysfunction, Left (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue